The first participant in the Amylyx stage three trial began receiving doses before Christmas!
The Amylyx trial, called ORION, aims to test if AMX0035can effectively slow progression of neurodegenerative diseases such as PSP. And also to see if it helps to improve movement in people living with PSP.
Amylyx is looking to recruit participants across North America, Japan and Europe (including the UK).
There will be 100 sites in total, six in the UK, including London, Oxford and Manchester.
PSPA will work with researchers across the six UK sites to aid recruitment, so don’t forget to sign up to our Research Register to receive the latest news.
For more information about the trial beginning, click here.
Further information about the trial and eligibility can be found, here.
